Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?

MLA

Steck, Andrea K., et al. “Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?” The Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 8, Aug. 2017, pp. 2873–80. EBSCOhost, https://doi.org/10.1210/jc.2016-4003.

APA

Steck, A. K., Xu, P., Geyer, S., Redondo, M. J., Antinozzi, P., Wentworth, J. M., Sosenko, J., Onengut-Gumuscu, S., Chen, W.-M., Rich, S. S., & Pugliese, A. (2017). Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes? The Journal of Clinical Endocrinology and Metabolism, 102(8), 2873–2880. https://doi.org/10.1210/jc.2016-4003

Chicago

Steck, Andrea K, Ping Xu, Susan Geyer, Maria J Redondo, Peter Antinozzi, John M Wentworth, Jay Sosenko, et al. 2017. “Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?” The Journal of Clinical Endocrinology and Metabolism 102 (8): 2873–80. doi:10.1210/jc.2016-4003.